Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CPN1 | P15169 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.30 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25151798 | 0.95 | SLC6A2 (0.35) | SMN1; SMN2CXCR4ALDH1A1CPN1CPB2 | |
| SCHEMBL20118762 | 0.95 | ALDH1A1 (0.38) | SMN1; SMN2CXCR4ALDH1A1CPN1CPB2 | |
| SCHEMBL27289508 | 0.95 | SLC6A2 (0.35) | SMN1; SMN2CXCR4ALDH1A1CPN1CPB2 | |
| SCHEMBL12309036 | 0.95 | SLC6A2 (0.35) | SMN1; SMN2CXCR4ALDH1A1CPN1CPB2 | |
| SCHEMBL18595685 | 0.93 | ALDH1A1 (0.43) | SMN1; SMN2CXCR4ALDH1A1CPN1CPB2 | |
| SCHEMBL21707956 | 0.92 | ALDH1A1 (0.40) | SMN1; SMN2CXCR4ALDH1A1TSHRLMNA | |
| SCHEMBL13451823 | 0.87 | ALDH1A1 (0.36) | SMN1; SMN2CXCR4ALDH1A1CPN1CPB2 | |
| SCHEMBL18595691 | 0.85 | ALDH1A1 (0.41) | ALDH1A1CPN1CPB2TSHRLMNA | |
| SCHEMBL19139659 | 0.85 | ALDH1A1 (0.41) | ALDH1A1CPN1CPB2TSHRLMNA | |
| SCHEMBL806895 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240024-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023173083-A1 | TETRAHYDROINDOLE DERIVATIVES AS EGFR AND/OR HER2 INHIBTORS USEFUL FOR THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-3894402-B1 | N-CONTAINING CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2023-07-05 | — | — | EP | disclosed |
| WO-2020120528-A1 | N-CONTAINING CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-18 | — | — | WO | disclosed |
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | SMN1; SMN2 3923/4885CXCR4 178/4885ALDH1A1 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.